BioSpace News Archive

Bayer announced today that prescription-strength Astepro® Allergy (Azelastine HCI .15%) is now available over-the-counter (OTC) in retail stores nationwide.

Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that it has completed its acquisition of CartiHeal.

Altamira Therapeutics today announced the publication of a peer-reviewed article in the scientific journal Biomaterials Advances titled, “Peptide-siRNA nanoparticles targeting NF-κB p50 mitigate experimental abdominal aortic aneurysm (AAA) progression and rupture” that covers a study conducted by a research group at Washington University, St. Louis, MO.

AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), announced today their publication in collaboration with researchers at Arizona State University (ASU) entitled, “Third COVID-19 Vaccine Dose Boosts Neutralizing Antibodies in Poor Responders” in Communications Medicine, part of the Nature family of journals.

Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it has entered into a strategic partnership agreement with CathWorks, a privately held company headquartered in Kefar Sava, Israel, which aims to transform how coronary artery disease (CAD) is diagnosed and treated.

Micropep, an ag-biotech company developing revolutionary biological micropeptide-based solutions for agriculture, announces the completion of a €8.75 million Series A1 financing round.

The latest market analysis report published by Reports and Data, titled ‘Global Breast Localization Wire Market – Forecast to 2030,’ thoroughly examines the Breast Localization Wire industry to provide essential data & information for the targeted readers.

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, has added another patent family to its molecular residual disease (MRD)-related IP portfolio, with priority to January 2013.

MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), today announces the signing of a strategic platform license (SPL) with LG Chem Ltd., a globally diversified chemical company established in petrochemical, advanced materials and bio-technology, aiming to create new value for its customers based on science.

According to Vision Research Reports, the global Point Of Care Diagnostics & Testing market size is expected to be worth around US$ 36.70 billion by 2030.